Cancer Therapy To Be Tested
Scientists at the University of
North Carolina at Chapel Hill are beginning safety trials of a promising new
way of treating certain cancers.
The researchers will administer increasing doses of a compound known as
PS341 to between 20 and 30 cancer patients to determine the highest doses
they can receive without developing side effects.
Earlier work suggests that the compound will be safe and that it might
boost success in treating people with stubborn cases of such blood-borne
malignancies as leukemia, myeloma and lymphoma, said Dr. Robert Orlowski,
assistant professor of medicine.
"Although it is too early to tell how beneficial it has been in shrinking
solid tumors, clinicians have observed few side effects.
Our experimental data suggest it could be useful in treating non-solid
tumors, and that's why we're doing this work," Orlowski said.